Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies aimed at treating immune diseases and cancer. Their lead product, soquelitinib (CPI-818), is a first-in-class oral therapy that selectively inhibits interleukin-2-inducible T cell kinase (ITK). This mechanism allows for the modulation of T cell responses, which is crucial for enhancing immune function against various cancers and autoimmune diseases. Soquelitinib has shown promise in clinical trials, particularly in treating refractory T-cell lymphomas and solid tumors, by promoting the activation and differentiation of T helper cells while inhibiting those that contribute to autoimmune responses.

In addition to soquelitinib, Corvus is advancing other clinical-stage programs, including ciforadenant (CPI-444) and mupadolimab (CPI-006). Ciforadenant targets the adenosine A2A receptor, which plays a significant role in immunosuppression within the tumor microenvironment, potentially enhancing the efficacy of immune responses against cancer. Mupadolimab is being evaluated as a front-line therapy for advanced non-small cell lung cancer (NSCLC) in combination with standard chemotherapy and immune checkpoint inhibitors. Together, these therapies represent Corvus's commitment to developing targeted treatments that leverage the immune system to combat cancer and immune-related disorders.

United States

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

Cancer

Central Nervous System (CNS)

Immune System Diseases

Skin Diseases

Corvus 

Blood cancer

Peripheral T-cell Lymphomas

CPI-818 is a small molecule drug given orally that has been shown to &nbsp;selectively inhibit ITK (interleukin-2-inducible T cell kinase). An &nbsp;enzyme, ITK is expressed predominantly in T cells and plays a role in T &nbsp;cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function.
<a href="https://www.corvuspharma.com/our-science/pipeline-programs/">Source</a>

Soquelitinib (CPI-818) 

Lung cancer

Non-small cell lung carcinoma

Renal cell carcinoma

CPI-006 targets and blocks the CD73 enzyme, inhibiting adenosine &nbsp;production by tumor cells, as well as acting on other important immune processes. CPI-006 enhances the activity and trafficking of immune cells, leading to improved cancer cell destruction.

Mupadolimab (CPI-006)

Autoimmune Lymphoproliferative Syndrome

Soquelitinib

Head and neck cancer

CPI-006 targets and blocks the CD73 enzyme, inhibiting adenosine &nbsp;production by tumor cells, as well as acting on other important immune processes. CPI-006 enhances the activity and trafficking of immune cells, leading to improved cancer cell destruction.

Mupadolimab + pembrolizumab

Ciforadenant, is a small molecule drug that is administered orally. It &nbsp;is an antagonist of the adenosine A2A receptor, meaning it blocks &nbsp;adenosine&nbsp;A2A receptors on immune cells. By precisely targeting this &nbsp;critical receptor on immune cells, ciforadenant may unleash their &nbsp;cancer-killing properties. Ciforadenant is designed to disable a tumor’s &nbsp;ability to subvert attack by the immune system by blocking the binding &nbsp;of adenosine in the tumor environment to the A2A receptor.
<a href="https://www.corvuspharma.com/our-science/pipeline-programs/">Source</a>

Ciforadenant +/- ipilimumab and nivolumab

Atopic dermatitis

Skin disease/disorder

COVID-19

CPI-006 activates B cells, leading to lymphocyte trafficking, plasmablast differentiation, and antigen specific antibody secretion. Robust humoral anti-viral immune responses have the potential to &nbsp;generate a diverse set of neutralizing antibodies to eliminate viruses &nbsp;and protect against re-infection, transmission, and the evolution of &nbsp;mutations that escape targeted therapeutics.
<a href="https://www.corvuspharma.com/our-science/pipeline-programs/">Source&nbsp;</a>

Corvus

Company Details